CLAUDIA GARCIA-MORALES

Dr. CLAUDIA GARCIA-MORALES

orcid

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 August 2009 in Retrovirology
Verified
Journal Article
Open access
PDF file
SÁSantiago Ávila-Ríos
Santiago Ávila-Ríos
COChristopher E Ormsby
Christopher E Ormsby
JCJonathan M Carlson
Jonathan M Carlson
HPHumberto Valenzuela Ponce
Humberto Valenzuela Ponce
JBJuan Blanco-Heredia
Juan Blanco-Heredia
GRGustavo Reyes-Teran
Gustavo Reyes-Teran
Mounting evidence indicates that HLA-mediated HIV evolution follows highly stereotypic pathways that result in HLA-associated footprints in HIV at the population level. However, it is not known whether characteristic HLA frequency distributions in different populations have resulted in additional unique footprints.

17 April 2018 in Scientific Reports
Verified
Journal Article
Open access
PDF file
HVHumberto Valenzuela-Ponce
Humberto Valenzuela-Ponce
SASelma Alva-Hernández
Selma Alva-Hernández
DGDaniela Garrido-Rodríguez
Daniela Garrido-Rodríguez
MSMaribel Soto-Nava
Maribel Soto-Nava
TGThalía García-Téllez
Thalía García-Téllez
GRGustavo Reyes-Terán
Gustavo Reyes-Terán
Associations between HLA class I alleles and HIV progression in populations exhibiting Amerindian and Caucasian genetic admixture remain understudied. Using univariable and multivariable analyses we evaluated HLA associations with five HIV clinical parameters in 3,213 HIV clade B-infected, ART-naïve individuals from Mexico and Central America (MEX/CAM cohort). A Canadian cohort (HOMER, n = 1622) was used for comparison. As expected, HLA allele frequencies in MEX/CAM and HOMER differed markedly. In MEX/CAM, 13HLA-A, 24HLA-B, and 14HLA-Calleles were significantly associated with at least one clinical parameter. These included previously described protective (e.g.B*27:05,B*57:01/02/03andB*58:01) and risk (e.g.B*35:02) alleles, as well as novel ones (e.g.A*03:01,B*15:39andB*39:02identified as protective, andA*68:03/05,B*15:30,B*35:12/14,B*39:01/06,B*39:05~C*07:02, andB*40:01~C*03:04identified as risk). Interestingly, both protective (e.g.B*39:02) and risk (e.g.B*39:01/05/06) subtypes were identified within the common and genetically diverseHLA-B*39allele group, characteristic to Amerindian populations. While HLA-HIV associations identified in MEX and CAM separately were similar overall (Spearman’s rho = 0.33, p = 0.03), region-specific associations were also noted. The identification of both canonical and novel HLA/HIV associations provides a first step towards improved understanding of HIV immune control among unique and understudied Mestizo populations.

8 December 2021 in Pathogens
Verified
Journal Article
Open access
PDF file
CGCLAUDIA GARCIA-MORALES
CLAUDIA GARCIA-MORALES
DTDaniela Tapia-Trejo
Daniela Tapia-Trejo
MMMargarita Matías-Florentino
Margarita Matías-Florentino
VQVerónica Sonia Quiroz-Morales
Verónica Sonia Quiroz-Morales
VDVanessa Montserrat Davila-Conn
Vanessa Montserrat Davila-Conn
SÁSantiago Ávila-Ríos
Santiago Ávila-Ríos
In response to increasing pretreatment drug resistance (PDR), Mexico changed its national antiretroviral treatment (ART) policy, recommending and procuring second-generation integrase strand-transfer inhibitor (INSTI)-based regimens as preferred first-line options since 2019. We present a four-year observational study describing PDR trends across 2017–2020 at the largest HIV diagnosis and primary care center in Mexico City. A total of 6688 baseline protease-reverse transcriptase and 6709 integrase sequences were included. PDR to any drug class was 14.4% (95% CI, 13.6–15.3%). A significant increasing trend for efavirenz/nevirapine PDR was observed (10.3 to 13.6%, p = 0.02). No increase in PDR to second-generation INSTI was observed, remaining under 0.3% across the study period. PDR was strongly associated with prior exposure to ART (aOR: 2.9, 95% CI: 1.9–4.6, p < 0.0001). MSM had higher odds of PDR to efavirenz/nevirapine (aOR: 2.0, 95% CI: 1.0–3.7, p = 0.04), reflecting ongoing transmission of mutations such as K103NS and E138A. ART restarters showed higher representation of cisgender women and injectable drug users, higher age, and lower education level. PDR to dolutegravir/bictegravir remained low in Mexico City, although further surveillance is warranted given the short time of ART optimization. Our study identifies demographic characteristics of groups with higher risk of PDR and lost to follow-up, which may be useful to design differentiated interventions locally.

1 December 2021 in Pathogens
Verified
Journal Article
Open access
PDF file
YVYanink Caro Vega
Yanink Caro Vega
FAFernando Alarid-Escudero
Fernando Alarid-Escudero
EEEva A. Enns
Eva A. Enns
SSSandra Sosa-Rubí
Sandra Sosa-Rubí
CCCarlos Chivardi
Carlos Chivardi
SÁSantiago Ávila-Ríos
Santiago Ávila-Ríos
We describe associations of pretreatment drug resistance (PDR) with clinical outcomes such as remaining in care, loss to follow-up (LTFU), viral suppression, and death in Mexico, in real-life clinical settings. We analyzed clinical outcomes after a two-year follow up period in participants of a large 2017–2018 nationally representative PDR survey cross-referenced with information of the national ministry of health HIV database. Participants were stratified according to prior ART exposure and presence of efavirenz/nevirapine PDR. Using a Fine-Gray model, we evaluated virological suppression among resistant patients, in a context of competing risk with lost to follow-up and death. A total of 1823 participants were followed-up by a median of 1.88 years (Interquartile Range (IQR): 1.59–2.02): 20 (1%) were classified as experienced + resistant; 165 (9%) naïve + resistant; 211 (11%) experienced + non-resistant; and 1427 (78%) as naïve + non-resistant. Being ART-experienced was associated with a lower probability of remaining in care (adjusted Hazard Ratio(aHR) = 0.68, 0.53–0.86, for the non-resistant group and aHR = 0.37, 0.17–0.84, for the resistant group, compared to the naïve + non-resistant group). Heterosexual cisgender women compared to men who have sex with men [MSM], had a lower viral suppression (aHR = 0.84, 0.70–1.01, p = 0.06) ART-experienced persons with NNRTI-PDR showed the worst clinical outcomes. This group was enriched with women and persons with lower education and unemployed, which suggests higher levels of social vulnerability.

10 February 2023 in Viruses
Verified
Journal Article
Open access
PDF file
RFRosa Flieller
Rosa Flieller
SCSusana Cabrera
Susana Cabrera
DRDora Ruchansky
Dora Ruchansky
AGAmalia Girón-Callejas
Amalia Girón-Callejas
MBMaría Brasesco
María Brasesco
SÁSantiago Ávila-Ríos
Santiago Ávila-Ríos
The first nationally representative cross-sectional HIV drug resistance (HIVDR) survey was conducted in Uruguay in 2018–2019 among adults diagnosed with HIV and initiating or reinitiating antiretroviral therapy (ART). Protease, reverse transcriptase, and integrase genes of HIV-1 were sequenced. A total of 206 participants were enrolled in the survey; 63.2% were men, 85.7% were >25 years of age, and 35.6% reported previous exposure to antiretroviral (ARV) drugs. The prevalence of HIVDR to efavirenz or nevirapine was significantly higher (OR: 1.82, p < 0.001) in adults with previous ARV drug exposure (20.3%, 95% CI: 18.7–22.0%) compared to adults without previous ARV drug exposure (12.3%, 11.0–13.8%). HIVDR to any nucleoside reverse transcriptase inhibitors was 10.3% (9.4–11.2%). HIVDR to ritonavir-boosted protease inhibitors was 1.5% (1.1–2.1%); resistance to ritonavir-boosted darunavir was 0.9% (0.4–2.1%) among adults without previous ARV drug exposure and it was not observed among adults with previous ARV drug exposure. Resistance to integrase inhibitors was 12.7% (11.7–13.8%), yet HIVDR to dolutegravir, bictegravir, and cabotegravir was not observed. The high level (>10%) of HIVDR to efavirenz highlights the need to accelerate the transition to the WHO-recommended dolutegravir-based ART. Access to dolutegravir-based ART should be prioritised for people reporting previous ARV drug exposure.

17 June 2022 in The Analyst
Verified
Journal Article
Closed access
PDF file
GGGaurav K. Gulati
Gaurav K. Gulati
NPNuttada Panpradist
Nuttada Panpradist
SSSamuel W. A. Stewart
Samuel W. A. Stewart
IBIngrid A. Beck
Ingrid A. Beck
CBCeejay Boyce
Ceejay Boyce
JLJames J. Lai
James J. Lai
The COVID-19 pandemic interrupted routine care for individuals living with HIV, putting them at risk of virologic failure and HIV-associated illness. Often this population is at high risk for exposure to SARS-CoV-2 infection, and once infected, for severe disease. Therefore, close monitoring of HIV plasma viral load (VL) and screening for SARS-CoV-2 infection are needed. We developed a non-proprietary method to isolate RNA from plasma, nasal secretions (NS), or both. The extracted RNA is then submitted to RT-qPCR to estimate the VL and classify HIV/SARS-CoV-2 status (i.e., HIV virologic failure or suppressed; SARS-CoV-2 as positive, presumptive positive, negative, or indeterminate). In contrived samples, the in-house RNA extraction workflow achieved a detection limit of 200-copies per mL for HIV RNA in plasma and 100-copies per mL for SARS-CoV-2 RNA in NS. Similar detection limits were observed for HIV and SARS-CoV-2 in pooled plasma/NS contrived samples. When comparing in-house with standard extraction methods, we found high agreement (>0.91) between input and measured RNA copies for HIV LTR in contrived plasma; SARS-CoV-2 N1/N2 in contrived NS; and LTR, N1, and N2 in pooled plasma/NS samples. We further evaluated this workflow on 133 clinical specimens: 40 plasma specimens (30 HIV-positive), 67 NS specimens (31 SARS-CoV-2-positive), and 26 combined plasma/NS specimens (26 HIV-positive with 10 SARS-CoV-2-positive), and compared the results obtained using the in-house RNA extraction to those using a commercial kit (standard extraction method). The in-house extraction and standard extraction of clinical specimens were positively correlated: plasma HIV VL (R2 of 0.81) and NS SARS-CoV-2 VL (R2 of 0.95 and 0.99 for N1 and N2 genes, respectively); and pooled plasma/NS HIV VL (R2 of 0.71) and SARS-CoV-2 VL (R2 of 1 both for N1 and N2 genes). Our low-cost molecular test workflow ($1.85 per pooled sample extraction) for HIV RNA and SARS-CoV-2 RNA could serve as an alternative to current standard assays ($12 per pooled sample extraction) for laboratories in low-resource settings.